Recent developments in the pharmacological treatment and prevention of corneal graft rejection

Authors: Banerjee S.; Dick A.D.

Source: Expert Opinion on Investigational Drugs, Volume 12, Number 1, 1 January 2003 , pp. 29-37(9)

Publisher: Informa Healthcare

Buy & download fulltext article:

OR

Price: $99.00 plus tax (Refund Policy)

Abstract:

At present, given the high initial success rate of corneal transplantation (although late survival is poor), immunosuppression is often reserved for ‘high-risk’ patients. Despite immune privilege, corneal graft rejection remains the leading cause of corneal allograft failure. Interpreting the limited and also restricted design of most trials, immunosuppressive therapy has not enjoyed the success seen in solid organ grafts. This review discusses the limited data available whilst proposing newer therapies that have developed as a result of our increased understanding of the immunobiology of corneal graft rejection.

Keywords: corneal transplantation; corticosteroids; cyclosporin A; immunosuppressants; mAb therapies; mycophenolate mofetil; tacrolimus

Document Type: Review article

Publication date: 2003-01-01

More about this publication?
Related content

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page